摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

penicillin V potassium | 132-98-9

中文名称
——
中文别名
——
英文名称
penicillin V potassium
英文别名
penicillin V potassium salt;penicillin VK;potassium;N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl]-2-phenoxyethanimidate
penicillin V potassium化学式
CAS
132-98-9
化学式
C16H17N2O5S*K
mdl
——
分子量
388.486
InChiKey
HCTVWSOKIJULET-LQDWTQKMSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    197-202°C
  • 比旋光度:
    D25 +223° (c = 0.2)
  • 密度:
    1.40
  • 溶解度:
    易溶于水,几乎不溶于乙醇(96%)。
  • 物理描述:
    Penicillin vk+ is an odorless white crystalline powder. Slightly bitter taste. pH (0.5% aqueous solution) 5 to 7.5. (NTP, 1992)
  • 颜色/状态:
    White, colorless crystalline powder
  • 气味:
    Odorless
  • 旋光度:
    Specific optical rotation: +223 deg at 25 °C/D (c= 0.2)
  • 解离常数:
    pKa= 2.73
  • 碰撞截面:
    182.7 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
  • 稳定性/保质期:
    基本性质:结晶固体,易溶于水。比旋光度[α]D²⁵值为+223°(c=0.2)。大鼠经口半数致死量大于1040 mg/kg。

计算性质

  • 辛醇/水分配系数(LogP):
    -3.63
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    124
  • 氢给体数:
    1
  • 氢受体数:
    6

ADMET

毒理性
  • 肝毒性
在接收第一代青霉素的人中,有报告称极少数病例出现了特异性的肝脏损伤。许多病例报告出现在病毒性肝炎血清学检测可用之前,并且许多描述的患者有多种原因导致肝病(如败血症),并且这些患者还在接受其他可能对肝脏有毒的药物。第一代青霉素可能会导致三种不同的肝脏损伤形式:(1) 在长期高剂量静脉注射青霉素时,会出现短暂的、无症状的血清转氨酶水平升高,(2) 与严重超敏反应相关的小幅肝脏损伤,(3) 特异性的、延迟性胆汁淤积性肝炎。这三种损伤形式可能出现在所有四代青霉素中,其中一些在某种青霉素形式中比另一种更常见。 静脉注射和肌肉注射高剂量青霉素可能会导致血清转氨酶升高,这通常是无需症状的,并且在停止治疗或换用另一种抗生素后迅速解决(案例1)。黄疸和碱性磷酸酶升高通常是缺席的或轻微的。这种肝毒性在苯唑西林和羧苄西林中最常见,但也可能出现在第一代青霉素的注射形式中。这种损伤形式似乎直接对肝脏有毒。 对青霉素有严重超敏反应的患者,如史蒂文斯-约翰逊综合症或过敏性休克,可能会有伴随的肝脏损伤和黄疸,但目前尚不清楚这是否代表真正的青霉素肝毒性,还是高热、休克和普遍免疫反应并发症。青霉素的全身性过敏反应可能会伴随肝脏、脾脏和肾脏的肉芽肿,但通常没有特定肝炎损伤的证据。几乎所有青霉素都与超敏反应有关,但肝脏损伤通常被过敏并发症(皮疹、发热、过敏性休克)所掩盖。 最后,孤立的病例报告显示,第一代青霉素可以引起延迟性胆汁淤积性肝炎,这可能是特异性的肝毒性。恶心、腹部不适、黄疸和瘙痒的症状通常在开始治疗后的1到4周出现,并且经常在完成一个疗程后的几天或几周后出现。血清酶模式通常是胆汁淤积性的,但如果在发作后立即检测,可能是混合性或肝细胞性的。免疫过敏特征很常见,但自身抗体形成是罕见的。大多数病例的严重程度为轻到中度,并且迅速解决(案例2)。这种延迟形式的特异性的胆汁淤积性肝炎是许多青霉素和头孢菌素的典型特征,其频率随着特定形式而变化。特异性的胆汁淤积性肝炎在天然青霉素中非常罕见,某些广谱青霉素(如氯唑西林、氟氯西林)中更为常见,在使用阿莫西林和阿莫西林克拉维酸时最常见。 可能性评分:C(可能是临床上明显肝脏损伤的罕见原因)。
Rare instances of idiosyncratic liver injury have been reported in persons receiving the first generation penicillins. Many case reports predated availability of serologic testing for viral hepatitis and many described patients with multiple reasons for having liver disease (such as sepsis) and who were receiving other potentially hepatotoxic agents. Three distinct forms of liver injury can occur with the first generation penicillins: (1) transient, asymptomatic elevations in serum aminotransferase levels with prolonged high doses of parenteral penicillin, (2) minor liver injury associated with severe hypersensitivity reactions, and (3) idiosyncratic, delayed cholestatic hepatitis. These three forms of injury probably occur with all four generations of penicillin, some being more common with one form of penicillin than another. High doses of intravenous and intramuscular penicillin can be associated with serum aminotransferase elevations that are usually asymptomatic and resolve rapidly with stopping therapy or switching to another antibiotic (Case 1). Jaundice and elevations in alkaline phosphatase are usually absent or mild. This type of hepatotoxicity is most common with oxacillin and carbenicillin, but can occur with parenteral forms of the first generation penicillins as well. This form of injury appears to be direct hepatotoxicity. Patients with severe hypersensitivity reactions to penicillin, such as Stevens-Johnson syndrome or anaphylaxis, may have an accompanying liver injury and jaundice, but it is not clear whether this represents true penicillin hepatotoxicity or a complication of hyperthermia, shock and generalized immune reactivity. Generalized allergic reactions to penicillin may be accompanied by granulomas in the liver, spleen and kidney, but are usually without evidence of specific hepatitis injury. Virtually all of the penicillins are associated with hypersensitivity reactions, but liver injury is usually overshadowed by the allergic complications (rash, fever, anaphylaxis). Finally, isolated case reports have shown that the first generation penicillins can cause a delayed cholestatic hepatitis that probably represents idiosyncratic hepatotoxicity. Symptoms of nausea, abdominal discomfort, jaundice and pruritus generally arise 1 to 4 weeks after starting therapy, and often a few days or weeks after completing a course. The serum enzyme pattern is usually cholestatic, but may be mixed or hepatocellular if tested soon after onset. Immunoallergic features are common, but autoantibody formation is rare. Most cases are mild-to-moderate in severity and resolve rapidly (Case 2). This delayed form of idiosyncratic cholestatic hepatitis is typical of many penicillins and cephalosporins, varying in frequency with the specific form. Idiosyncratic, cholestatic hepatitis is quite rare with the natural penicillins, more common with certain broad spectrum penicillins (cloxacillin, flucloxacillin) and is most common with amoxicillin with clavulanic acid. Likelihood score: C (probable rare cause of clinically apparent liver injury).
来源:LiverTox
毒理性
  • 相互作用
青霉素与氨基糖苷类药物在体外混合会导致显著的相互灭活;如果这些抗生素要同时使用,应该在不同的部位给药,至少间隔1小时。/青霉素/
Mixing penicillins with aminoglycosides in vitro has resulted in substantial mutual inactivation; if these groups of antibacterials are to be administered concurrently, they should be administered at separate sites at least 1 hour apart. /Penicillins/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
甲氨蝶呤与青霉素类药物同时使用会导致甲氨蝶呤的清除率降低,增加甲氨蝶呤中毒的风险;这被认为是由于肾脏小管分泌的竞争所致;患者应密切监测;可能需要增加亚叶酸钙的剂量,并延长给药时间。/青霉素类药物/
Concurrent of /methotrexate/ with penicillins has resulted in decreased clearance of methotrexate and in methotrexate toxicity; this is thought to be due to competition for renal tubular secretion; patients should be closely monitored; leucovorin doses may need to be increased and administered for longer periods of time. /Penicillins/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
由于抑菌药物(如氯霉素、红霉素、磺胺类药物或四环素)可能会干扰青霉素在治疗脑膜炎或其他需要快速杀菌效果的情况下的杀菌作用,因此最好避免同时使用;然而,有时会同时给儿科患者使用氯霉素和阿莫西林。/青霉素/
Since bacteriostatic drugs /Chloramphenicol, erythromycins, sulfonamides, or tetracyclines/ may interfere with the bactericidal effect of penicillins in the treatment of meningitis or in other situations in which a rapid bactericidal effect is necessary, it is best to avoid concurrent therapy; however, chloramphenicol and ampicillin are sometimes administered concurrently to pediatric patients. /Penicillins/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
当同时使用时,丙磺舒减少青霉素的肾小管分泌;这种效应导致血清浓度增加和延长,消除半衰期延长,以及毒性风险增加。青霉素和丙磺舒常同时使用,以治疗性传播疾病或其他需要高和/或长期抗生素血清和组织浓度的感染。/青霉素/
Probenecid decreases renal tubular secretion of penicillins when used concurrently; this effect results in increased and prolonged serum concentrations, prolonged elimination half-life, and increased risk of toxicity. Penicillins and probenecid are often used concurrently to treat sexually transmitted diseases or other infections in which high and/or prolonged antibiotic serum and tissue concentrations are required. /Penicillins/
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
100 万单位酸的一剂可达到大约 2 到 3 微克/毫升的血浆峰值水平,但钾盐可提供 4.5 到 9 微克/毫升的水平。
A dose of 1,000,000 units of the acid gives peak plasma levels of about 2 to 3 ug/ml, but the potassium salt will provide levels of 4.5 to 9 ug/ml.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
青霉素VK比青霉素V提供更快、更高的血药浓度。
Penicillin VK provides faster and higher blood levels of antibiotic than Penicillin V.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
100万单位剂量的这种酸可以产生大约2到3微克/毫升的血浆峰值水平,但钾盐的血浆水平为4.5到9微克/毫升。
A dose of 1,000,000 units of the acid gives peak plasma levels of about 2 to 3 ug/ml, but the potassium salt will provide levels of 4.5 to 9 ug/ml.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
青霉素VK比青霉素V能更快地提供更高水平的抗生素血液浓度。
Penicillin VK provides faster and higher blood levels of antibiotic than Penicillin V.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • TSCA:
    Yes
  • 危险品标志:
    Xn
  • 安全说明:
    S22,S26,S36/37,S45
  • 危险类别码:
    R22,R42/43
  • WGK Germany:
    3
  • 海关编码:
    2941109400
  • 危险品运输编号:
    NONH for all modes of transport
  • RTECS号:
    XH9275000
  • 储存条件:
    贮存时,请密封并置于阴凉干燥处保存。

SDS

SDS:9ebee79684ada6738ff674631d9ee47e
查看

制备方法与用途

概述

青霉素V钾属于青霉素类抗生素,其抗菌谱与青霉素相同。它对多数革兰阳性菌、革兰阴性球菌、个别革兰阴性杆菌(如嗜血杆菌属)、螺旋体和放线菌均有抗菌活性。然而,超过90%的葡萄球菌株,包括金黄色葡萄球菌和凝固酶阴性葡萄球菌,可以产生β内酰胺酶使青霉素V钾水解而失活。青霉素V钾对大多数敏感菌株的活性比青霉素弱2~5倍,并且对产青霉素酶的菌株无抗菌作用。

生物活性

青霉素V钾是一种口服活性抗生素,能够抑制链球菌、艰难梭菌和金黄色葡萄球菌的生长。它可用于治疗中耳炎、鼻窦炎、咽炎和扁桃体炎等疾病。

体外研究
  • 青霉素V钾 (0.002-8.0 mg/L) 抑制链球菌的生长,最低抑菌浓度 (MICs) 为 0.004-0.008 mg/L。
  • 青霉素V钾 (0.002-8.0 mg/L) 抑制艰难梭菌的生长,最低抑菌浓度90 (MIC90) 为 8 mg/L。
  • 青霉素V钾 (0.004-0.063 mg/L; 18 小时) 抑制金黄色葡萄球菌的生长,其 MIC 为 0.016 mg/L。
体内研究
  • 青霉素V钾 (0.063-0.25 mg/kg; 单次皮下注射) 在小鼠股肌肉中抑制金黄色葡萄球菌的过度生长。
  • 青霉素V钾 (100 mg/kg; 每日一次口服给药 5 天) 避免了大鼠急性化脓性中耳炎 (AOM) 的严重感染。
  • 青霉素V钾 (2 mg/kg; 单次皮下注射) 具有半衰期为 61 分钟和平均 AUC 为 0.47 mg/L·h。
动物模型 特定病原体自由(SPF)雄性瑞士小鼠 (20-25 g),接种金黄色葡萄球菌
剂量 0.063, 0.13, 0.25 mg/kg
给药方式 单次皮下注射
结果 在剂量为 0.25 mg/kg 的情况下,减少了菌落形成单位 (CFU) 数(1.34×10^7 病毒/毫升),与对照组相比(3.5×10^7 病毒/毫升)
用途

青霉素V钾用作抗生素。

反应信息

  • 作为反应物:
    描述:
    penicillin V potassium 在 ammonium sulfate 、 sodium间氯过氧苯甲酸三甲氧基磷 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 40.0h, 生成 δ-(L-α-aminoadipyl)-L-cysteinyl-D-3,4-didehydrovaline
    参考文献:
    名称:
    I-α-氨基己二酰基-半胱氨酰-d-3,4-二氢加氢缬氨酸的合成,一种有效的异青霉素合成酶抑制剂
    摘要:
    标题肽(1)已经合成,并与无头孢头孢菌的无细胞活性提取物一起孵育,未观察到向活性抗生素的转化。但是,在与Arnstein三肽(ACV)共同孵育时(2),观察到了对ACV转化为异青霉素N的强烈抑制作用。
    DOI:
    10.1016/0040-4020(82)85002-3
  • 作为产物:
    描述:
    苯氧乙酰氯碳酸氢钠 作用下, 以 丙酮正丁醇 为溶剂, 反应 0.35h, 生成 penicillin V potassium
    参考文献:
    名称:
    [EN] CEPHALOSPORIN DERIVATIVES AND METHODS OF USE
    [FR] DÉRIVÉS DE CÉPHALOSPORINE ET LEURS PROCÉDÉS D'UTILISATION
    摘要:
    这项发明提供了头孢菌素衍生物,用于杀灭或抑制微生物的传播,如非复制的结核分枝杆菌,并用于治疗传染病。
    公开号:
    WO2014071283A1
点击查看最新优质反应信息

文献信息

  • (2R,4S)-2-Aminomethyl-5,5-dimethyl-1,3-thiazolidine-4-carboxylic Acid Dihydrochloride: Synthesis, Epimerization, and Derivatives
    作者:Peter Imming
    DOI:10.1002/ardp.19953280115
    日期:——
    The preparation of the title compound 6a from penicillamine 5 or from penicillins 7, the spectroscopic data and stereochemical assignments are given. 6a quickly epimerizes at C‐2 in dilute aqueous solution. Details are given along with the preparation of the new thiazolidines 10–13 from 6.
    由青霉胺5或由青霉素7制备标题化合物6a,给出了光谱数据和立体化学归属。6a 在稀水溶液中在 C-2 处快速差向异构化。详细信息与新的噻唑烷 10-13 从 6 的制备一起给出。
  • ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
    申请人:Meng Charles Q.
    公开号:US20140142114A1
    公开(公告)日:2014-05-22
    The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
    本发明涉及以下式(I)的新型驱虫化合物: 其中 Y和Z分别是双环碳环或双环杂环基团,或者Y或Z中的一个是双环碳环或双环杂环基团,另一个是烷基,烯基,炔基,环烷基,苯基,杂环基或杂芳基,以及变量X 1 ,X 2 ,X 3 ,X 4 ,X 5 ,X 6 ,X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物,以及它们用于治疗和预防动物寄生虫感染的用途。
  • [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
    申请人:MERIAL INC
    公开号:WO2018093920A1
    公开(公告)日:2018-05-24
    The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
    本发明提供了公式(I)的环状脱氨肽化合物,其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物,对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法,用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
  • DERIVATIVES OF RELEBACTAM AND USES THEREOF
    申请人:ARIXA PHARMACEUTICALS, INC.
    公开号:US20200102307A1
    公开(公告)日:2020-04-02
    Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.
    Relebactam的衍生物、使用Relebactam的衍生物的治疗方法,特别是与β-内酰胺类抗生素结合使用以及其制药组合物已被披露。Relebactam的衍生物适合口服给药。
  • [EN] COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:ACHILLION PHARMACEUTICALS INC
    公开号:WO2017035360A1
    公开(公告)日:2017-03-02
    Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    化合物、使用方法和制备抑制补体因子D的方法,包括式(I)的药用盐或其组合物。本文描述的抑制剂针对因子D并抑制或调节补体级联反应。本文描述的因子D的抑制剂减少了过度激活的补体。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物